Dr. Daniel D. Esmaili, MD

Dr. Esmaili practices at Oakhurst Surgical Center, LLC in Beverly Hills, California.

Dr. Esmaili's NPI, 1629279864, was assigned on May 29, 2007. Dr. Esmaili graduated from Keck School of Medicine of USC in 2003. Dr. Esmaili holds California license A91049.

Dr. Esmaili's primary practice is Oakhurst Surgical Center, LLC, at 9001 Wilshire Blvd, Beverly Hills, CA 90211 in Los Angeles County. The practice phone is (310) 273-8094.

Dr. Esmaili's primary practice is Oakhurst Surgical Center, LLC in Beverly Hills, California. Dr. Esmaili is also affiliated with PIH Health Good Samaritan Hospital. Dmand AI also links Dr. Esmaili to 4 more medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Esmaili practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Esmaili's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Esmaili is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Esmaili's licenses on file in 4 states: California, Florida, Massachusetts and Rhode Island.

Dmand AI lists age-related macular degeneration, cataract, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and glaucoma among the conditions Dr. Esmaili treats.

CMS data shows 33,737 Medicare services from Dr. Esmaili across 18 procedure codes in 2024, for 1,050 Medicare patients. Medicare paid $2,873,380 for them.

CMS counts 1,050 Medicare patients who saw Dr. Esmaili in 2024. The largest group is 65 to 74, with 399 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 32% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Esmaili's median patient age at 67, with 53% women.

In 2024, Dr. Esmaili wrote 493 Medicare Part D claims for 185 patients. 67% of them were for generic drugs. CMS names the drug for 404 of them, across 13 drugs with 11 or more claims each, at $55,654 in total drug cost. In 2023, CMS named 305 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Esmaili for performance year 2024, reported as part of a group. Dr. Esmaili accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Esmaili, published from 2015 to 2018. 2015 was the busiest year, with 3. Dr. Esmaili's most frequent co-authors are Dean Eliott, MD, Christopher Michael Andreoli, MD and David S. Boyer, MD.

Dmand AI links Dr. Esmaili to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Macular Degeneration and Retinal Degeneration.

CMS Open Payments shows 106 general payments to Dr. Esmaili from 9 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 61% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $36,571.

Dmand AI lists 10 awards for Dr. Esmaili, most recently Superdoctors Southern California Rising Stars in 2015.

Dr. Esmaili graduated from Keck School of Medicine of USC in 2003. Dr. Esmaili is a member of AAO.

Dr. Esmaili is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.